Stock Market Reviews

MIRM (Mirum Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on MIRM (Mirum Pharmaceuticals, Inc.). Explore the news page 6 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Mirum Pharmaceuticals Says First Patient Enrolled in Phase 2 Fragile X Syndrome Therapy Trial of MRM-3379
  Mirum Pharmaceuticals (MIRM) said Monday it has enrolled the first participant in its phase 2 clinic
  Dec 1, 2025 - $MIRM
• Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
  FOSTER CITY, Calif., December 01, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).
  Dec 1, 2025 - $MIRM
• Biotechs Are On A Big Run, And Two Stocks Have Buy Points
  Biotech stocks remain prevalent on the IBD 50 list of winning growth names. While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases. Biotech stocks have made tremendous progress off April lows.
  Nov 28, 2025 - $MIRM
• Mirum Pharmaceuticals (MIRM): Exploring Valuation After Steady Momentum and Pipeline Developments
  Mirum Pharmaceuticals (MIRM) has seen a slight dip in its share price over the past week, moving down by about 1%. Over the past month, though, the stock is up roughly 2%, reflecting steady momentum. See our latest analysis for Mirum Pharmaceuticals. Zooming out, Mirum Pharmaceuticals' recent moves hint at continued momentum rather than a short-term spike. The 1-year total shareholder return stands at an impressive 58.94%, and the year-to-date share price return of nearly 71% suggests that...
  Nov 26, 2025 - $MIRM
• Penn Capital Dumps Entire Chart Industries Stake
  Chart Industries terminated one planned merger to be acquired by Baker Hughes instead.
  Nov 25, 2025 - $MIRM
• Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
  FOSTER CITY, Calif., November 25, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:
  Nov 25, 2025 - $MIRM
• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  FOSTER CITY, Calif., November 11, 2025--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Nov 11, 2025 - $MIRM
• Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
  FOSTER CITY, Calif., November 07, 2025--Mirum Pharma Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
  Nov 7, 2025 - $MIRM
• Mirum Pharmaceuticals (MIRM): Discounted Valuation Reinforces Bullish Narrative on Profit Breakthrough Potential
  Mirum Pharmaceuticals (MIRM) is still unprofitable, but the company has managed to cut losses at a rate of 2.1% per year over the past five years. Looking ahead, analysts expect Mirum's earnings to surge 70.27% annually, while revenue is set to climb 16.4% per year, outpacing the broader US market’s projected 10.5% growth. With forecasts pointing to profitability within three years and a share price well below estimated fair value, investors see reasons to be optimistic based on Mirum’s rapid...
  Nov 6, 2025 - $MIRM
• Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
  Mirum Pharmaceuticals Inc (MIRM) reports a nearly 50% increase in revenue and achieves positive net income, marking a significant milestone in its financial performance.
  Nov 5, 2025 - $MIRM